Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Ag

Category: Markets

Published: 2026-07-16T11:35:17.000Z

Arbutus Biopharma, along with its licensee Genevant, has filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. The company also announced it received approximately $178 million from Moderna as part of a settlement agreement for past litigation and plans to return up to $230 million in capital to shareholders, primarily through share repurchases, commencing in Q3 2026. These actions follow ongoing U.S. enforcement proceedings and anticipate a dividend from Genevant's parent.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.